RECRUITING

Persuasive Health Communication Intervention for HIV/HCV

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

A major impediment to emergency department (ED)-based HIV/HCV screening success is that often ED patients at risk for, or later diagnosed with, HIV and HCV decline testing. In this R01 project, the research team will assess how well a promising, easy-to-use, one-time, minimal-training-needed, very brief persuasive health communication intervention (PHCI) increases acceptance of testing among adult ED patients who either currently, formerly or never injected drugs and initially declined HIV/HCV screening. The research team will conduct a randomized, controlled trial (RCT) at EDs within the Mount Sinai Health System to compare the efficacy of the PHCI when delivered by a video vs. an HIV/HCV counselor. Patients who initially declined HIV/HCV screening will be stratified by injection-drug use (IDU) history cohorts: (1) current/former PWIDs, (2) never/non-PWIDs. Within each IDU history cohort, the research team will randomly assign participants (1:1:1) to a PHCI delivered by: (1) a video with captions, (2) a video without captions, (3) an HIV/HCV counselor. This R01 project will be conducted at Mount Sinai affiliate hospitals EDs. For Aim 2, the research team will determine if screening acceptance is similar across IDU history cohorts. For Aim 3, the research team will further compare the two delivery forms of the PHCI through a health economics assessment, both independent of IDU history and within each IDU history cohort.

Official Title

Evaluation of a Persuasive Health Communication Intervention Designed to Increase HIV/HCV Screening Among Emergency Departments Patients Who Currently, Formerly or Never Injected Drugs.

Quick Facts

Study Start:2023-12-04
Study Completion:2027-12-08
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05968573

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * ≥18 years-old
  2. * Speak English or Spanish, and able to provide informed consent for study participation
  3. * Not HIV AND HCV infected/Antibody+ (per EHR review and patient report)
  4. * Not already participating in a HIV or HCV study (e.g., HIV PrEP, HIV vaccine)
  5. * Not tested for HIV OR HCV within the past 12 months (per EHR review and patient report)
  1. * \<18 years old
  2. * Unable to speak Spanish or English
  3. * HIV or HCV positive
  4. * Currently enrolled in another HIV or HCV research study
  5. * Has tested for HIV or HCV in the past 12 months

Contacts and Locations

Study Contact

Roland C Merchant, MD
CONTACT
(212) 524-9814
Roland.Merchant@mountsinai.org

Principal Investigator

Roland C Merchant, MD
PRINCIPAL_INVESTIGATOR
Icahn School of Medicine at Mount Sinai

Study Locations (Sites)

Icahn School of Medicine at Mount Sinai
New York, New York, 10128
United States

Collaborators and Investigators

Sponsor: Icahn School of Medicine at Mount Sinai

  • Roland C Merchant, MD, PRINCIPAL_INVESTIGATOR, Icahn School of Medicine at Mount Sinai

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-12-04
Study Completion Date2027-12-08

Study Record Updates

Study Start Date2023-12-04
Study Completion Date2027-12-08

Terms related to this study

Additional Relevant MeSH Terms

  • Human Immunodeficiency Virus (HIV)
  • Hepatitis C (HCV)